Sleep Like A Baby Again? The Surprising New Use For A Diabetes Drug
Researchers from the University of California San Diego School of Medicine, with international collaborators, have spearheaded a global study showcasing tirzepatide's potential. Known for managing type 2 diabetes, tirzepatide may now serve as the first effective drug therapy for obstructive sleep apnea (OSA). This disorder involves repeated episodes of irregular breathing due to partial or complete blockage of the upper airway.
The findings, published on June 21, 2024, in the New England Journal of Medicine, underscore the treatment's potential to enhance the quality of life for millions affected by OSA worldwide. "This study marks a significant milestone in the treatment of OSA," said Dr. Atul Malhotra, lead author and professor at UC San Diego School of Medicine.
OSA can lower blood oxygen levels and is linked to increased cardiovascular risks like hypertension and heart disease. Recent studies led by Malhotra estimate that nearly 936 million people globally suffer from OSA. The new study involved 469 participants with clinical obesity and moderate-to-severe OSA. They were recruited from nine countries, including the U.S., Australia, and Germany.
Participants either used or did not use continuous positive airway pressure (CPAP) therapy, a common sleep apnea treatment that keeps airways open during sleep. Patients received either 10 or 15 mg of tirzepatide by injection or a placebo over 52 weeks. The impact was evaluated through two Phase III, double-blinded, randomized, controlled trials.
Significant Findings
Researchers observed that tirzepatide significantly reduced the number of breathing interruptions during sleep, a key measure of OSA severity. This improvement was much greater than in those given a placebo. Some participants even reached a point where CPAP therapy might not be necessary.
The drug also improved other OSA-related aspects, such as reducing cardiovascular risk factors and improving body weight. The most common side effect reported was mild stomach issues.
Expert Opinions
"Historically, treating OSA meant using devices like CPAP machines during sleep," said Malhotra. "However, its effectiveness relies on consistent use. This new drug treatment offers a more accessible alternative for individuals who cannot tolerate or adhere to existing therapies.
"Malhotra emphasized that combining CPAP therapy with weight loss could be optimal for improving cardiometabolic risk and symptoms. Tirzepatide targets specific underlying mechanisms of sleep apnea, potentially leading to more personalized and effective treatments.
Having a drug therapy for OSA represents a significant advancement in the field. "It means we can offer an innovative solution," Malhotra added. "This breakthrough opens the door to a new era of OSA management for people diagnosed with obesity.
"Next steps include conducting clinical trials to examine longer-term effects of tirzepatide.
Sign in with Google